Tag: Patients
Search News
Blood test predicts chemotherapy resistance in prostate cancer
11th November 2021
Research conducted at Barts Cancer Institute (BCI), Queen Mary University of London, indicates that regular blood tests before and during chemotherapy for prostate cancer can detect whether or not a patient is resistant or developing resistance to treatment with a drug called docetaxel. Ms Caitlin Davies, a PhD student at BCI, presented the findings from her PhD research at the National Cancer Research Institute (NCRI) Festival, which is taking place from 8-12th November 2021.
Read more
OPTIMA: Improving treatment for cancer patients through artificial intelligence
12th October 2021
Professors Claude Chelala and Louise Jones from Barts Cancer Institute, Queen Mary University of London, are part of a €21.3 million public-private research programme that will seek to use artificial intelligence to improve care for patients with prostate, breast and lung cancer.
Read more
Combining medicine with blood cancer research
3rd September 2021
This Blood Cancer Awareness Month, we spoke with Dr John Riches, Clinical Senior Lecturer at Barts Cancer Institute (BCI), Queen Mary University of London. Dr Riches is a clinician scientist who splits his time between BCI where he leads a group researching blood cancer in our Centre for Haemato-Oncology and directs the MSc Cancer & Clinical Oncology Programme, and St Bartholemew’s Hospital where he treats blood cancer patients.
Read more
Study identifies biomarker that could help to diagnose pancreatic cancer
29th June 2021
Researchers from Barts Cancer Institute, Queen Mary University of London, have identified a protein that could be used to aid in the diagnosis of pancreatic cancer. Findings from the new study suggest that a protein called pentraxin 3 may be a specific diagnostic biomarker – or biological measure – for pancreatic cancer, with the ability to differentiate pancreatic cancer from other non-cancerous conditions of the pancreas.
Read more
Study suggests blood test could guide precision treatment in bladder cancer
16th June 2021
A blood test that can detect tiny amounts of circulating cancer DNA may be able to identify risk of cancer recurrence and guide precision treatment in bladder cancer following surgery, according to a clinical study led by Professor Tom Powles from Barts Cancer Institute at Queen Mary University of London and Barts Health NHS Trust. The findings from the study, published today in Nature, may change our understanding of cancer care following surgery.
Read more
Screening for ovarian cancer did not reduce deaths
13th May 2021
A large-scale randomised trial of annual screening for ovarian cancer did not succeed in reducing deaths from the disease, despite one of the screening methods tested detecting cancers earlier, according to results published in The Lancet.
Read more